March 31, 2026
1 min read

Novo Nordisk cuts 400 roles at troubled Bloomington site

Amid a major corporate overhaul, Novo Nordisk is pruning the ranks at its Bloomington, Indiana, production facility, which contributes to the blockbuster GLP-1 medications Ozempic and Wegovy.

Leave a Reply

Your email address will not be published.

Previous Story

Supreme Court rules against Colorado ban on ‘conversion therapy’ for LGBTQ kids

Next Story

Ardena’s US plant buy pays off as CDMO endures rough geopolitical waters

Previous Story

Supreme Court rules against Colorado ban on ‘conversion therapy’ for LGBTQ kids

Next Story

Ardena’s US plant buy pays off as CDMO endures rough geopolitical waters

Latest from Blog

Go toTop